The FDA just approved a trial to make old cells young again. This has never happened before.

The science traces back to 2006, when a Japanese researcher named Shinya Yamanaka discovered that just four genes — now called the Yamanaka factors — could reset an adult cell to an embryonic-like state. The implication was extraordinary: ageing, at the cellular level, was not a one-way road. It might be reversible. The catch was that fully reset cells lose their identity entirely, and can form tumours.

What followed was twenty years of careful, frustrating work to apply the factors partially — long enough to roll back the cellular clock, short enough to keep the cell doing its job. Mouse studies showed it could be done. The hard question was whether it could be done in a person, safely, on purpose, in a way the FDA would approve.

In January 2026, the answer became yes. The FDA cleared Life Biosciences' Investigational New Drug applicationGlossaryAn IND is the FDA permission slip a drug developer needs before they can give an experimental treatment to humans. It's a milestone. for partial cellular reprogramming in humans — the first such trial in history.

Why it starts with the eye

The first trial does not target ageing in general. It targets NAION — non-arteritic anterior ischaemic optic neuropathy — a sudden, devastating form of optic-nerve damage that has no approved treatment and almost always leaves patients with permanent vision loss in the affected eye.

The eye is, regulatorily speaking, a forgiving organ to test in. The dose can be precisely localised. The treated tissue is small. The contralateral eye serves as an internal control. And NAION patients have, by every existing standard of care, no other option — which is the kind of clinical context in which the FDA is willing to allow genuinely novel therapies to be tested.

The FDA has been notably open and forward-thinking in how it engages with this approach.

What partial reprogramming actually does

The therapy delivers a controlled, time-limited dose of three of the four Yamanaka factorsGlossaryFour genes (Oct4, Sox2, Klf4, c-Myc) that can reset a cell's age. Discovered in 2006 by Shinya Yamanaka, who won a Nobel for it. (the fourth, c-Myc, is omitted because of its cancer-promoting tendencies). Treated retinal ganglion cells are exposed to the factors briefly — long enough to reset epigeneticGlossaryThe instructions sitting on top of DNA that tell each cell which genes to read and which to ignore. Ageing changes these instructions — and they can, it turns out, be changed back. markers associated with ageing, but not long enough to lose their identity as eye cells.

In animal models, this has restored vision in cases of optic-nerve damage that were thought to be permanent. The neurons did not regrow; they were re-enabled. Cells that had stopped doing their job started doing it again.

What it could mean, eventually

If partial reprogramming works in the optic nerve, the next targets are obvious — and large. Glaucoma. Age-related macular degeneration. Spinal cord injury. Eventually, perhaps, neurons in the brain itself: Parkinson's disease, certain dementias, ALS. Anywhere we currently say "the damage is permanent," there is now a research programme asking whether it actually is.

This is not the finish line. It is, more accurately, the starting line of a race the field has been preparing for since 2006. First-patient enrolments for the NAION trial are happening now. First readouts will not come until late 2027 at the earliest.

What we are watching next

Beyond Life Biosciences, several groups are pursuing related approaches. Altos Labs (the well-funded reprogramming-focused biotech founded in 2022) has not yet entered the clinic but is presumed close. Calico, Retro Biosciences, and at least three university-affiliated groups have programmes at preclinical stages. And the regulatory precedent set by this single FDA decision will, quietly, shape the clinical timeline for the next decade of longevity medicine.